<DOC>
	<DOCNO>NCT01203527</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetics ( PK ) anti-flu medication , Tamiflu pregnancy determine extent pregnancy may affect currently recommend dosage medication .</brief_summary>
	<brief_title>A Study Pharmacology Tamiflu Pregnancy</brief_title>
	<detailed_description>The emergence novel H1N1 influenza virus raise concern among public health official public alike . Although initial report suggest risk serious disease death less initially fear , continue experience suggest disease major impact public 's health . To address urgent public health challenge , center Obstetric-Fetal Pharmacology Research Units Network ( OPRU ) recruit total 75 pregnant woman ( 25 per trimester singleton pregnancy ) receive oseltamivir suppose influenza infection . When possible , recruit woman twin gestation determine fetal number affect drug pharmacokinetics . We anticipate significant number multi-fetal gestation ( &lt; 10 ) even limit data might prove useful population give tremendous change renal drug clearance normally see group woman . An additional 25 healthy non-pregnant woman study define pregnancy- relate change PK oseltamivir carboxylate . We study woman therapy , perform steady state pharmacokinetic analysis . This study perform 3 day oral therapy optimize possibility steady state concentration achieve . We : 1. collect biological fluid ( plasma urine ) characterize pharmacology drug ; 2. collect check swab DNA allow study impact single nucleotide polymorphisms drug hand disease expression ; 3. develop assay partner others develop assay oseltamivir primary metabolite , oseltamivir carboxylate ; 4. compare pharmacokinetics oseltamivir metabolite trimester pregnancy evaluate whether gestational age impact drug 's pharmacokinetics ; 5. assess impact fetal number drug 's pharmacokinetics ; 6. ask participant GI tolerance drug side effect may experience , especially related mood psychiatric well ; 7. pregnant subject study , possible , obtain delivery maternal umbilical cord blood evaluate placental transport especially deliver proximate ( within 3 day ) drug treatment .</detailed_description>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>1 . Taking start oral oseltamivir presume influenza viral infection prophylaxis 2 . Able give inform consent 3 . Pregnant female singleton multifetal gestation healthy nonpregnant female ( ancillary study ) 1 . Unable take medication orally 2 . Renal failure creatinine &gt; 1.5 3 . Hct &lt; 28</criteria>
	<gender>Female</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>H1N1 influenza</keyword>
	<keyword>Swine flu</keyword>
	<keyword>Oseltamivir</keyword>
	<keyword>Tamiflu</keyword>
	<keyword>Pregnancy</keyword>
</DOC>